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Abstract
Anti-Leishmanial drug therapy faces significant challenges related to cytotoxicity and drug resistance. Thus, new and effi-
cient anti-Leishmanial drugs need to be identified. Due to their broad-spectrum antimicrobial and also immunomodulatory 
activities, antimicrobial peptides (AMPs) have attracted considerable attention. In this study, we comparatively assessed the 
anti-Leishmanial activities of two recently identified AMPs (dicentracin-like and moronecidine-like) and the well-known 
AMP piscidin from the hybrid striped bass. AMPs were first assessed against Leishmania major promastigotes using MTS. 
Subsequently, macrophages were infected with L. major and treated with AMPs to evaluate anti-amastigotes activity of 
AMPs, and non-infected macrophages were treated with AMPs to determine cytotoxicity against mammalian cells using 
MTS. The induction of factors limiting L. major growth (IL-12, TNF-α and reactive oxygen species (ROS)) by AMPs 
was measured by ELISA and dichlorofluorescin-diacetate (DCFH-DA) assay, respectively. Piscidin was more efficacious 
against L. major promastigotes as compared to dicentracine-like or moronocidin-like peptides, whereas, dicentracine-like 
and moronocidin-like peptide exhibited a higher activity against L. major amastigotes compared to piscidin. In turn, pisci-
din was most cytotoxic in non-infected macrophages compared to the other two AMPs. A direct association was observed 
between hydrophobicity of AMPs and their anti-promastigote and cytotoxic activities. Dicentracine-like or moronocidin-like 
peptides induced higher levels of IL-12, TNF-α and ROS in macrophages compared to piscidin. Collectively, our results 
suggest that dicentracine-like and moronocidin-like peptides represent potentially promising multi-functional therapeutic 
agents that might not only directly kill L. major but also induce anti-Leishmania factors that can limit L. major growth and 
intracellular survival.
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Introduction
The genus Leishmania includes several species, which are 
the causative agents of either cutaneous, mucocutaneous or 
visceral leishmaniasis in mostly tropical countries (Ansari 
et al. 2016). More than 350 million people are at risk of 
infection, 2.4 million disability-adjusted life years (DALYs) 
are lost due to leishmaniasis, and 1-1.5 million cases of cuta-
neous and 500,000 cases of visceral leishmaniasis occur each 
year, with 20,000 to 40,000 deaths (Mitra and Mawson 2017; 
Gharavi et al. 2011a, b). Treatments to control leishmaniasis 
are mainly based on chemotherapy. Currently used drugs 
include pentavalent antimonial, amphotericin B, liposomal 
amphotericin B, miltefosine, paromomycin and pentamidine. 
However, adverse side effects such as nephrotoxicity and 
teratogenicity, as well as the prohibitive costs, long duration 
of treatment, and the potential for resistance formation, are 
important obstacles that impair treatment efficiency (Sundar 
and Chakravarty 2015; Ponte-Sucre et al. 2017).
Antimicrobial peptides (AMPs) are biologically active 
molecules of the innate immune system, particularly in 
invertebrates (Chiou et al. 2005; Sathyamoorthi et al. 2019; 
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Shafiee et al. 2017; Zhang et al. 2009), that were first discov-
ered in the 1980’s to exhibit activity against invading patho-
gens such as bacteria, fungi and viruses (Chiou et al. 2002; 
Mohammad et al. 2015; Lei et al. 2019; Nayak et al. 2018). 
They are cationic and hydrophobic peptides, which can get 
incorporated into the negatively charged microbial mem-
brane through electrostatic interactions, forming pores and 
leading to cell death(Chiou et al. 2002; Mohammad et al. 
2015; Lei et al. 2019). It has been postulated that peptides 
kill pathogens by several mechanisms, including membrane 
destabilization, cytoplasmic leakage, collapse of metabolic 
pathways and also impairment of protein and nucleic acid 
synthesis (Guilhelmelli et al. 2013; Chifiriuc et al. 2014). 
Currently, several AMPs are being evaluated in preclinical 
and clinical trials to treat infectious diseases. Furthermore, 
two lipopeptides including polymyxin B and polymyxin 
E are currently used to treat topical infections and infec-
tion caused by multidrug-resistant gram-negative bacteria 
(Ngamprasertchai et al. 2018; Vaara 2019).
Studies are ongoing to find effective and novel anti-par-
asitic agents with low side effects in the host (Mor 2009; 
Torrent et al. 2012). The mechanisms of action of AMPs that 
lead to anti-Leishmania activities are being studied (Marr 
et al. 2012). The selectivity toxicity AMPs against Leishma-
nia and the low host cell cytotoxicity renders them highly 
attractive as peptide-based drugs, either in combination with 
already approved therapeutics or as a monotherapy (Cobb 
and Denny 2010).
In our previous study, we characterized two novel anti-
microbial peptides, called moronecidin-like (from Asian sea 
bass fish) and moronecidine-like (from hippocampus comes) 
peptides, which exhibited efficient antibacterial activity 
against both gram-positive and gram negative bacteria, 
and their antibacterial activities were somewhat depend-
ent on electrostatic interactions with bacterial cell walls 
(Mohammadi et al. 2018; Taheri et al. 2018). In this study, 
we evaluated the anti-Leishmania properties of moroneci-
din-like and dicentracin-like AMPs against promastigotes 
and intracellular amastigotes of L. major cultured in mac-
rophages, in comparison to the well-characterized AMP pis-
cidin. The three AMPs exhibited considerable anti-Leishma-
nial activities, with piscidin being more efficacious against 
promastigotes, and dicentracine-like and moronecidin-like 
exhibiting higher and specific activities against the amas-
tigote stage of L. major and low host cell toxicity. In mac-
rophages, dicentracine-like and moronecidin-like induced 
the expression of IL-12, TNF-α and reactive oxygen species 
(ROS), which contributed to their anti-amastigote activities. 
This indicates that dicentracine-like and moronecidin-like 
AMPs should be further considered as potential multifunc-
tional agents for the treatment of Leishmania infections.
Materials and Methods
Sequence Analysis of Peptides
To predict physicochemical features (Table 1) of AMPs, 
their amino acid sequence was submitted in the Prot Param 
(http://www.expas y.ch/tools /protp aram.html). Furthermore, 
helical wheel projection (http://rzlab .ucr.edu/scrip ts/wheel 
/wheel .cgi).
was used to predict helical wheel and hydrophilic and 
hydrophobic interface on the secondary structure of the 
peptide.
Synthetic AMPs
The AMPs (dicentracine-like, moronecidine-like and pisci-
din) were synthesized by N-(9-fluorenyl) methoxycarbonyl 
(Fmoc) chemistry (pepmic, Suzhou, Co China). The pep-
tides were C-terminally modified with amid group, and puri-
fied using RP-HPLC (SHIMADZU) employing an Inertsil 
ODS-SP (4.6 × 250 mm × 5 µm) column and elution with 
a 0–100% H2O/acetonitrile gradient containing 0.1% trif-
luoroacetic acid (TFA). The homogeneity of peptides was 
Table 1  Physicochemical 
properties of AMPs peptides
Name Dicentracin-like (P1) Moronecidin-like (P2) Piscidin (P3)
Sequence FLRSLLRGAKAI-










Polar/non-polar residues (%) 50/50 40.91/59.09 54.55/45.45
Hydrophobic face residues F G I L A A LWY L F A A L G A F W F W F L V I I I F V G F
Non-polar face hydrophobicity < H> 1.25 1.25 1.49
Hydrophobicity <H>/retention time 0.321 /20.518 0.375 /17.474 0.644 /21.588
Water solubility Good solubility Good solubility Poor solubility
Hydrophobic moment <µH> 0.55 0.50 0.55
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evaluated by HPLC, and the molecular masses were deter-
mined with mass spectrometry (MS) (Figs. S1, S2 and S3). 
The lyophilized peptides were suspended in peptide solution 
(0.01% acid acetic and 0.2% bovine serum albumin (BSA)), 
and stored at 20 °C as peptide stock (2 mg/ml).
Parasite Culture
All Culture Materials were Bought from Sigma Aldrich Co 
(UK)
Leishmania major promastigotes (MRHO/IR/75/ER) were 
cultivated at 26 °C in RPMI1640 Glutamax medium supple-
mented with 10% heat-inactivated fetal bovine serum (FBS), 
0.25% hemin, 0.1% biotin, 10 mM adenine, 1% penicillin-
streptomycin. For all experiments, stationary-phase L. major 
promastigotes was used because of high infectivity of L. 
major in this phase (Wozencraft and Blackwell 1987). For 
this purpose, L. major promastigotes has been cultured for 
5 days, were harvested and washed in phosphate buffered 
saline (PBS) prior to use.
The macrophage cell line RAW264.7 was cultured in 
DMEM medium containing 10.00% FBS and penicillin-
streptomycin at 37 ̊C under 5%  CO2. Macrophages were 
collected at almost 80% confluence.
Evaluation of Anti‑Leishmanial Activity of AMPs
L. major promastigotes were counted in a Neubauer hemo-
cytometer and seeded into 96-wel microplates at 1 × 106 cells 
per well. After 24 h, parasites were treated with 15.5, 31 
or 62 µM of peptides and incubated for 24 hours at 24 °C. 
The parasite viability was then determined using the MTS 
assay as described elsewhere (Lynn et al. 2011). The optical 
density was read at 570 nm and wells containing non-treated 
parasites were used as growth control. Each concentration 
was assessed in triplicate wells.
Microscopy
L. major promastigotes were exposed to 15.5, 31 or 62 µM 
of peptides in 96-wel microplates (1 × 106 cells per well) and 
incubated for 24 h at 24 C. The morphology of treated versus 
non-treated parasite was then assessed by light microscopy 
using an inverted microscope at 400 X magnification.
Cytotoxicity in RAW 264.7 Macrophage Cell Line
RAW 264.7 macrophages were seeded into 96-well micro-
plates at 4 × 105 cells per well. Afterward, 15.5, 31 or 62 µM 
of peptides or peptide solution were added, and cells were 
cultured for 48 hours at 37 °C/5%  CO2. The viability of mac-
rophages was assessed by MTS assay as previously described 
(Lynn et al. 2011). Each peptide concentration was assessed 
in duplicates. In this experiment, some wells without parasites 
were used as blank.
Measurements of Anti‑amastigote Activity of AMPs
To assess anti-amastigote activity of AMPs, peritoneal 
macrophages were obtained from BALB/c mice. These ani-
mals were maintained under the animal license permit No. 
R.BPUMS.REC.1397.064 and experiments were approved by 
the ethics committee of Bushehr University of Medical Sci-
ences. Macrophages isolated from Balb/c mice were placed 
into 8-well chamber slides (Thermo Scientific Nunc Lab-Tek, 
USA ) (8 × 105 marcrophages/well) and were cultured in RPMI 
1640 medium containing 10% FBS at 37 ̊C/5%  CO2 for 5 h. 
Non-adherent cells were removed, and adherent macrophages 
were infected with stationary phase L. major promastigotes at 
a 1:5 ratio (macrophage/amastigote) and cultured for 5 h. Wells 
were washed with RPMI 1640 medium three times to remove 
non-phagocytosed parasites, and infected cells were treated 
with AMPs peptide (15.5 or 31 µM), ovalbumin-derived pep-
tide (OVA peptide) as non-AMP peptide (15.5 µM) or pep-
tide solution (as control infection) for 72 hr. Macrophages 
were then washed with PBS, fixed in methanol for 1 min and 
stained with 4’, 6-diamidino-2-phenylindole (DAPI; Sigma-
Aldrich, St. Louis, USA). The slides were analyzed with 
 NucleoCounter® NC-200™ (Chemometec, Allerod, DK) and 
the number of intracellular parasites in 100 macrophages were 
counted and expressed relative to those within macrophages 
treated with peptide solution (control infection) multiply 
by100.
Measurement of Reactive Oxygen Species (ROS) 
Production in Macrophages in Response to AMP 
Treatment
RAW 264.7 macrophage cells (1 × 105 cells/ml) were cultured 
in 48-well microplate, treated with the AMP peptides (15.5 
or 31 µM), OVA peptide as non-AMPs peptide (15.5 µM), 
the peptide solution as a negative control or LPS as positive 
control (100 ng/ml), and further cultured for 20 h. The pro-
duction of ROS within macrophages was measured by 2′, 
7′-dichlorofluorescin-diacetate (DCFH-DA) assay as described 
elsewhere (Fan et al. 2017). Briefly, the cells were treated with 
DCFH-DA, followed by incubation for 1 h and washed twice 
with PBS. Finally, intracellular fluorescence was quantified 
using the fluorescence micro plate reader (BioTek Synergy4, 
USA) at 485/530 nm.
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Assessment of Cytokine Responses in Macrophages 
in Response to AMP Treatments
RAW264.7 cells were seeded at 2 × 104 cells/well in a 
48-well plate overnight. Cells were exposed to AMPs 
(15.5 or 31 µM), ovalbumin peptide as non-AMP peptide 
(15.5 µM), peptide solution, or LPS as positive control 
(100 ng/ml), and then further cultured for 24 h at 37 C/5% 
CO2. Culture supernatants were collected and cytokine 
content (TNF-α, IL-12) was analyzed by indirect ELISA, 
according to the protocol provided by manufacture (Abcam, 
UK).
Statistical Analysis
The results and graphs are shown as mean the standard devi-
ations (SD) as indicated. Differences between control and 
peptide-treated samples were analyzed with Prism GraphPad 




The piscidin peptide exhibited the lowest positive net charge 
and lower solubility relative to dicentracine-like or monoro-
cidine-like AMPs (Table − 1). Furthermore piscidin had the 
most hydrophobic non-polar face as compared to dicentra-
cine-like or monorocidine-like. The central residues of the 
nonpolar face of dicentracine-like and monorocidine-like (9 
and 16 residues, respectively) are positioned by low hydro-
phobic residues including alanine and glycine, whereas the 
corresponding residues in piscidin are of higher hydrophobic 
residues (Isoleucine 9 and 16, respectively) (Fig. 1).
Evaluation of Anti‑promastigote Activity
The ability of AMPs to kill promastigotes in the stationary-
phase was evaluated to determine the direct cytotoxic activ-
ity against L. major. MTS assay and microscopic observa-
tion were used. MTS data showed (Fig. 2) that all peptides 
possess dose-dependent cytotoxic activity against L. major 
promastigotes. Dicentracine-like and piscidin exhibit greater 
activity against L. major as compared to morecidine-like 
with piscidin being the most efficacious of the three AMPs. 
Microscopy showed that piscidin, in comparison to the other 
AMPs, induced cellular deformation (rod-like shape) of pro-
mastigotes and inhibited cluster formation parasites, even 
at the lower peptide concentrations (15.5 or 31 µM). At the 
highest concentrations (62 µM), piscidin induced promstig-
ote lysis (Figs. S4, S5, 6). Dicentracine-like exhibited a more 
pronounced ability to induce cellular deformation (rod-like 
shape) and inhibited cluster formation of promastigotes at 
31 µM of peptide concentration.
Evaluation of cytotoxic activity of peptides 
on macrophage cell line
The cytotoxic activity of peptides against macrophages 
was determined using the MTS assay. As shown in Fig. 3, 
dicentracin-like and moronecidin-like did not exhibit cyto-
toxic activity against macrophages at 31 µM or lesser peptide 
concentration, but even stimulated macrophage proliferation 
at 31 µM peptide, whereas piscidin was cytotoxic against 
macrophages at this peptide concentration (31 µM).
Fig. 1  Helical wheel projections of dicentracine-like (Dic-L) morone-
cidin-like (Mor-L) and Piscidin (Pis) peptides. Residues are num-
bered starting from the N terminus. Residues that are higlyh hydro-
phobic and positively charged are shown in red and blue, respectively. 
Arrows represents the central residues (A9, A16) of the non-polar 
face in the helical wheel model of AMPs
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Evaluation of Anti‑amastigote Activity of AMPs
Infected macrophages were treated with the AMPs, and 
counting of intracellular amastigotes revealed a decreased 
number of amastigotes in AMPs treated cells relative to 
those treated with non-AMP peptide. Interestingly moron-
ocidin-like and dicentracin-like showed more pronounced, 
and virtually similar, anti-amastigote activity than pisci-
din, and the effect was dose-dependent (Fig. 4).
ROS Production in Macrophages After Exposure 
to AMPs
The ability of the peptide to induce ROS production in 
macrophages was evaluated by DCFH-DA assay. Mac-
rophages treated with moronocidin-like and dicentracin-like 
produced significantly high amounts of ROS as compared 
to those treated with piscidin, non-AMP peptide or pep-
tide solution(Fig. 5). An increase in the concentration of 
Fig. 2  Direct cytotoxic activity assessment of AMPs against L. major 
promastigotes. The promastigotes were exposed to 15.5, 31 or 62 µM 
or peptide solution. The parasite viability was determined using the 
MTS assay. Some well without parasites was used as blank, and some 
control wells with Leishmania and without peptide (peptide solution) 
are considered as 100% viable. Three independent experiments were 
performed, and the values are expressed as mean ± SD of those three 
independent experiments. Cytotoxic activity of AMP was compared 
to peptide solution using one-way analysis of variance (ANOVA). 
Differences at p < 0.05 were considered significant (***p < 0.001, 
**p < 0.01, and *p < 0.05)
Fig. 3  Cytotoxic activity assess-
ment of AMPs against the mac-
rophage cell line RAW 264.7. 
RAW 264.7 macrophages were 
exposed to 15.5, 31 or 62 µM 
of AMPs or peptide solution. 
The viability of macrophages 
was determined by MTS assay. 
The values are expressed as 
mean ± SD for three independ-
ent experiments. Differences at 
p < 0.05 were considered signifi-
cant (***p < 0.001, **p < 0.01, 
and *p < 0.05). Cytotoxic 
activity of each peptide was 
compared to peptide solution 
using one-way analysis of vari-
ance (ANOVA)
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moronocidin-like and dicentracin-like peptides up to 31 µM 
induced the increased ROS production, while no statisti-
cally significant change was observed in the production of 
piscidin-induced ROS.
Cytokine Responses in Macrophages After Exposure 
to AMPs
Cytokine response of macrophages was measured 
after exposure of cells to AMPs or LPS. High levels of 
TNF-α and IL-12 were measured in the culture superna-
tants of macrophages treated with moronocidin-like and 
dicentracin-like peptides, as compared to those treated 
with piscidin, non-AMP peptide or peptide solution 
(Fig. 6). Furthermore no statistically significant differ-
ence was observed in the level of piscidin-induced TNF-α 
and IL-12 as compared to those induced with non-AMP 
peptide or peptide solution. An increase in the concentra-
tion of moronocidin-like and dicentracin-like peptides up 
to 31 µM similarly induced the increased levels of TNF-α 
and IL-12, while no statistically significant change was 
observed in the levels of TNF-α and IL-12 produced by 
piscidin.
Fig. 4  Cytotoxic activity assessment of the AMPs against intracellu-
lar Leishmania amastigotes. Adherent peritoneal macrophages were 
infected with L. major promastigotes and cultured for 5 h, followed 
by treatment with AMPs (15.5, 31  µM) or peptide solution. Mac-
rophages were fixed and stained with DAPI, and intracellular amas-
tigotes were quantified. The values are expressed as mean ± SD for 
three independent experiments. Differences at p < 0.05 were consid-
ered significant (***p < 0.001, **p < 0.01, and *p < 0.05). The anti-
amastigote activity of each peptide was compared to piscidin peptide 
using one-way analysis of variance (ANOVA).
Fig. 5  Measuring ROS gen-
eration in macrophages. RAW 
264.7 macrophages were treated 
with AMPs (15.5 or 31 µM), 
non-AMP peptide, peptide solu-
tion or LPS, and then intracel-
lular ROS were measured using 
the fluorescence-based DCFH-
DA assay at 485/530 nm. 
The values are expressed as 
mean ± SD of three independ-
ent experiments. Differences at 
p < 0.05 were considered signifi-
cant (***p < 0.001, **p < 0.01, 
and *p < 0.05. The levels of 
ROS generation of each peptide 
were compared to peptide solu-
tion using one-way analysis of 
variance (ANOVA)
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Discussion
Cutaneous leishmaniasis, caused by L. major and L. tropica, 
is a main health problem in various provinces of Iran (Ghar-
avi et al. 2011a, b). There is no approved vaccine for prophy-
laxis of leishmaniasis in the endemic regions, and treatment 
is suboptimal, causing side effects. Consequently, there is an 
obvious and urgent need for developing affordable, safe and 
efficacious drugs against leishmaniasis (Fuertes et al. 2008).
In the current study, we compared the anti-L. major 
activities of the three AMPs dicentracine-like, morone-
cidin-like, and piscidin (Mohammadi et al. 2018; Taheri 
et al. 2018). The three AMPs exhibit dose dependent activ-
ity against L. major promastigotes, with piscidin being the 
most efficacious one as compared to the other two peptides, 
and induced promastigote lysis at a high peptide concentra-
tion. The most likely explanation for the high cytotoxicity 
of piscidin against promastigotes may be owing to its high 
hydrophobic nonpolar face relative to the other two pep-
tides. Prior studies demonstrated that peptides with highly 
hydrophobic nonpolar face possess more propensities to the 
cell membrane, which in turn leads to increased cytotoxic-
ity (Irazazabal et al. 2016; Taheri et al. 2019). In addition, 
piscidin also exhibited the highest cytotoxic activity against 
the macrophage cell line. This is consistent with earlier 
studies that had demonstrated the high cytotoxicity activ-
ity of piscidin against mammalian cells such as Hela cell 
and human red blood cells. (Kim et al. 2010; Kumar et al. 
2016). In a previous study, we demonstrated that a reduction 
of hydrophobicity at the nonpolar face of piscidin through 
amino acid substitution resulted in decreased cytotoxicity 
(Taheri et al. 2019).
In contrast to what was seen with promastigotes, morone-
cidine- like and dicentracine-like were more potent than pis-
cidin against L. major amastigotes. This is consistent with 
the observation that moronecidine- like and dicentracine-like 
peptides promoted the proliferation of macrophage cells. T 
helper1(Th1)-associated cytokines (especially interferon-γ, 
TNF-α and IL-12) are known as the key factors in the 
induction of protective immunity against L. major infection 
(Dayakar et al. 2019), this cytokines are up-regulated upon 
signaling of NF-κB and MAPK pathways (Wang et al. 2019).
Given that AMPs enhance macrophage function through 
TLR4-induced NF-κB and MAPK signaling (Wang et al. 
2019), we studied the influence of AMPs on the expression 
and induction of limiting factors on L. major growth (IL-12, 
TNF-α and ROS) in macrophages.
Dicentracine-like and moronecidin-like peptides were 
capable to induce IL-12, TNF-α and ROS, while non-AMP 
peptides did not. This result was consistent with previous 
study that demonstrated immunomodulatory activities of 
AMPs through the production of type 1 T helper (TH1) - 
polarizing cytokines (IL-12 and TNF-α) (Agier et al. 2015). 
Furthermore, Zheng et al. (Zheng et al. 2007) demonstrated 
that Cathelicidin LL-37 (a human AMPs), induced the 
generation of ROS in macrophages. AMPs-induced IL-12 
and TNF-α cytokines could activate NK cells to produce 
interferon (IFN)-γ, a key cytokine for polarization of T 
cells towards a Th1 immune response, and also activate 
macrophages cells to produce ROS and nitric oxide (NO), 
thereby protects the host cells through killing of intracellular 
amastigotes(Dayakar et al. 2019; Roma et al. 2016).
In this study, dicentracine-like and moronecidin-like 
treatements induced higher levels IL-12, TNF-α and ROS 
Fig. 6  Secretion of tumor necrosis factor (TNF alpha) and IL-12 by 
RAW 264.7 macrophages in response to peptides. RAW 264.7 mac-
rophages were treated with AMPs, non-AMP peptide, LPS or pep-
tide solution, and then the presence of TNF-α or IL-12 in culture 
supernatants was quantified by ELISA. The values are expressed as 
mean ± SD for three independent experiments. Differences at p < 0.05 
were considered significant (***p < 0.001, **p < 0.01, and *p < 0.05). 
Cytokine concentrations of medium supernatants from AMP treated 
macrophages were compared to peptide solution using one-way anal-
ysis of variance (ANOVA)
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compared to piscidin, and this might be due to the high cyto-
toxic activity of piscidin against macrophage, leading to the 
reduction of piscidin-induced productions(IL-12, TNF-α and 
ROS). Considering that IL-12, TNF-α and ROS act as key 
factors for intracellular L. major amastigote growth inhibi-
tion (Roma et al. 2016), the greater anti-amastigote activ-
ity of dicentracine-like and moronecidin-like peptides than 
piscidin peptide is mainly linked to their ability to induce the 
production of IL-12, TNF-α and ROS (indirect anti-amastig-
ote activity). This function corresponds to the well-known 
role of AMPs in the innate immune system (Diamond et al. 
2009). Furthermore, considering that piscidin peptide was 
disable to induce IL-12, TNF-α and ROS production, the 
greater anti-amastigote activity of piscidin peptide compared 
to non-AMP peptides could be due to its direct cytotoxic 
activity against intracellular L. major amastigote (direct 
anti-amastigote activity ), following the internalization of 
piscidin into macrophage cells. This result was consistent 
with the great cytotoxic activity of piscidn peptide against 
promastigote form. In agreement with this hypothesis, pre-
vious studies demonstrated intracellular antiviral activity of 
AMPs, via the internalization into infected cell and interrup-
tion of viral replication(Chessa et al. 2020).
Taken together, these AMPs could act as multifunctional 
agent against L. major not only through direct killing of L. 
major, but also modulation of proinflamatory cytokines and 
the activation of macrophage that might synergistically con-
trol leishmania infection. However, further experiments will 
be required to verify the anti-Leishmania activity of theses 
AMPs in the mouse model.
Conclusions
In the current study, we characterized two peptides with neg-
ligible toxicity (dicentracine-like and moronecidine-like), 
that not only exhibited direct cytotoxicity against L. major 
but also induced limiting L. major growth (proinflamatory 
cytokines and ROS) in macrophage cells. These two peptides 
suggested as attractive and efficient multi-functional thera-
peutic agent again leishmaniasis.
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